Abstract
Objectives Cardiovascular disease is a leading cause of mortality in systemic sclerosis (SSc). We investigated the association between SSc and the occurrence of both cardiovascular and thromboembolic events using the Clinical Practice Research Datalink (CPRD). Methods A validated case-ascertainment strategy identified SSc patients in the CPRD. A cohort study design examined rates of coronary arterial disease (CAD), cerebrovascular disease, peripheral artery disease (PAD) and venous thromboembolism (VTE) in SSc patients matched to non-SSc comparators by age, sex and location in a 1:6 ratio. Prevalent and incident cases of SSc were analysed separately. Cox regression analysis was used to determine hazard ratios for event occurrence, adjusted for traditional cardiovascular risk factors. Results We identified 877 eligible incident cases of SSc who were matched to 5262 patients without SSc (83.7% female), with a mean follow-up of 8 years. We identified a higher background prevalence of CAD, PAD and VTE at baseline (pre-dating diagnosis) in the SSc cohort. There was a significantly increased risk of CAD, PAD, peripheral venous thromboses and pulmonary embolism during follow-up in SSc compared with the non-SSc group (adjusted hazard ratios between 1.84-3.01), particularly amongst males. There was no increased risk of cerebrovascular disease. Conclusions We have identified an increased risk of cardiovascular events and VTE, both prior to a diagnosis of SSc and within 8 years of SSc diagnosis. Work is needed to establish the mechanism of arterial/venous thrombotic events in SSc. This insight will facilitate more targeted and effective preventative strategies and improve outcomes in SSc.
| Original language | English |
|---|---|
| Pages (from-to) | 5330-5337 |
| Number of pages | 8 |
| Journal | Rheumatology |
| Volume | 64 |
| Issue number | 10 |
| Early online date | 30 May 2025 |
| DOIs | |
| Publication status | Published - 1 Oct 2025 |
Funding
This work was funded with matched funding from Scleroderma Raynaud’s UK (SRUK) and the Bath Institute for Rheumatic Diseases.
| Funders |
|---|
| Scleroderma and Raynaud's UK |
| Bath Institute For Rheumatic Diseases |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Cardiovascular and venous thromboembolic events in systemic sclerosis: Epidemiological analysis of the Clinical Practice Research Datalink'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS